OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
OncoPrecision's ONC001, a first-in-class antibody-drug conjugate (ADC) targeting CD64, has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting, December 6–9, 2025, in Orlando, Florida.
ONC001 targets CD64, a myeloid-restricted receptor widely expressed in chronic myelomonocytic leukemia (CMML) and M4/M5 acute myeloid leukemia (AML), including therapy-resistant subsets.
It was developed using OncoPrecision's proprietary platform integrating large-scale patient-derived biology and AI-enhanced high-throughput screening to identify actionable cellular vulnerabilities and optimize the antibody, payload, and linker chemistry to reduce off-target toxicity.
Preclinical data to be presented include selective targeting of patient-derived CMML and AML cells, robust activity in samples resistant to standard therapies, and compelling in vivo efficacy across heterotopic and orthotopic models.
The presentation will be given by Dr. Gastón Soria, Co-Founder and Chief Scientific Officer of OncoPrecision, highlighting the novel therapeutic approach designed to overcome resistance mechanisms in aggressive blood cancers.
ONC001 is currently advancing through IND-enabling studies and represents a differentiated approach to treatment, with no prior approved or clinical-stage therapies exploiting CD64 as a target in monocytic leukemia.
OncoPrecision is leveraging patient-derived biology and AI-based discovery to develop precision medicines with a high probability of clinical success in hematologic malignancies and solid tumors.